Clinical Trial Update: PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pre-operative gefitinib in resectable EGFR mutation-positive non-small cell lung cancer with sector sequencing for biomarker d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED